No data to show
XSTO
PAX
Market cap156mUSD
Jun 24, Last price
78.60SEK
1D
-1.01%
1Q
8.26%
IPO
598.67%
Name
Paxman AB (publ)
Chart & Performance
P/E
37.18
P/S
5.91
EPS
2.11
Div Yield, %
—
Shrs. gr., 5y
3.48%
Rev. gr., 5y
24.30%
Revenues
253m
+20.41%
Net income
40m
+382.55%
CFO
39m
+150.15%
Profile
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. Paxman AB (publ) was founded in 1996 and is based in Karlshamn, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 253,007 20.41% | 210,117 34.05% | 156,746 62.93% | |||||
Cost of revenue | 77,587 | 63,698 | 57,325 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 175,420 | 146,419 | 99,421 | |||||
NOPBT Margin | 69.33% | 69.68% | 63.43% | |||||
Operating Taxes | 1,304 | (361) | 1,762 | |||||
Tax Rate | 0.74% | 1.77% | ||||||
NOPAT | 174,116 | 146,780 | 97,659 | |||||
Net income | 40,196 382.55% | 8,330 -180.69% | (10,324) -19.19% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 13,485 | 11,038 | 12,728 | |||||
Long-term debt | 808 | 2,532 | 4,257 | |||||
Deferred revenue | 4,257 | |||||||
Other long-term liabilities | 5,676 | 3,961 | (4,257) | |||||
Net debt | (26,017) | (11,411) | (21,155) | |||||
| Cash flow | ||||||||
Cash from operating activities | 39,104 | 15,632 | 2,686 | |||||
CAPEX | (16,188) | (11,724) | (35,692) | |||||
Cash from investing activities | (24,496) | (25,329) | (36,691) | |||||
Cash from financing activities | 721 | (3,414) | (169) | |||||
FCF | 148,944 | 144,413 | 79,464 | |||||
| Balance | ||||||||
Cash | 40,310 | 24,981 | 38,092 | |||||
Long term investments | 48 | |||||||
Excess cash | 27,660 | 14,475 | 30,303 | |||||
Stockholders' equity | 27,342 | 8,688 | ||||||
Invested Capital | 183,963 | 124,013 | 120,374 | |||||
ROIC | 113.07% | 120.12% | 75.99% | |||||
ROCE | 94.61% | 104.47% | 76.18% | |||||
| EV | ||||||||
Common stock shares outstanding | 19,081 | 19,081 | 19,012 | |||||
Price | 65.60 78.26% | 36.80 -14.62% | 43.10 -33.69% | |||||
Market cap | 1,251,712 78.26% | 702,180 -14.31% | 819,439 -27.84% | |||||
EV | 1,225,695 | 690,769 | 808,608 | |||||
EBITDA | 191,638 | 165,029 | 116,839 | |||||
EV/EBITDA | 6.40 | 4.19 | 6.92 | |||||
Interest | 4,663 | 7,346 | ||||||
Interest/NOPBT | 3.18% | 7.39% | ||||||